Additional CEO Share Purchase
Renalytix plc announced that its Chief Executive Officer, James McCullough, purchased 500 American Depositary Shares (ADS) on September 11th and 15th, 2026, at an average price of US$4.30 per ADS, for a total investment of US$2,148. These purchases bring his total interest in the company to 3,472,096 Ordinary Shares, representing 0.58% of the issued share capital. This insider buying activity may signal confidence in the company's future prospects.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 16 September 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that on 11 September and 15 September 2026 James McCullough, Chief Executive Officer, bought a total of 500 American Depositary Shares (ADS) at an average price of US$4.30 per ADS. ADS consist of 50 Ordinary Shares of £0.0025 each.
Following these purchases, James McCullough is interested in 3,472,096 Ordinary Shares1 representing 0.58% of the issued share capital of the Company.
| a) | Name | James McCullough |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive O fficer |
| b) | Initial notification /Amendment | Initial Notification |
| a) | Name | Renalytix plc |
| b) | LEI | 213800NTOH3FK3WER551 |
| a) | Description of the financial instrument, type of instrument | American Depository Shares (ADS) which consist of 50 Ordinary Shares at £0.0025 each |
| Identification code | GB00BYWL4Y04 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| $4.42 | 250 | 11 September |
| $ 4.17 | 2 50 | 1 5 September |
| d) | Aggregated information | |
| - Aggregated volume | 5 00 | |
| - Price | $2,148 | |
| e) | Date of the transactions | 11 and 15 September 2026 |
| f) | Place of the transaction | OTC New York |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.